Skip to main content

Tykerb and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Tykerb (lapatinib).

Moderate

lapatinib food

Moderate Food Interaction

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of lapatinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

ADJUST DOSING INTERVAL: Food can significantly increase the oral bioavailability of lapatinib. According to the manufacturer, lapatinib peak plasma concentration (Cmax) was approximately 2.5- and 3-fold higher and systemic exposure (AUC) 3- and 4-fold higher when administered with a low fat meal (5% fat; 500 calories) or with a high-fat meal (50% fat; 1000 calories), respectively, compared to fasting. Dividing the daily dose also resulted in an approximately 2-fold higher systemic exposure at steady state compared to the same total dose administered once daily.

MANAGEMENT: Patients treated with lapatinib should preferably avoid the consumption of grapefruit or grapefruit juice. The manufacturer recommends that lapatinib be administered at least one hour before or one hour after a meal. The lapatinib dose is administered once daily and should not be divided.

References

  1. "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals (2007):

Switch to consumer interaction data

Moderate

High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

HER2 inhibitors - CHF

Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity. Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF. Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions. Evaluate cardiac function before, during, and upon completion of treatment. Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further. It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.

References

  1. "Product Information. Herceptin (trastuzumab)." Genentech PROD (2001):
  2. "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals (2007):
  3. "Product Information. Perjeta (pertuzumab)." Genentech (2012):
  4. "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech (2022):
  5. "Product Information. Margenza (margetuximab)." Almirall (2021):
View all 5 references

Tykerb drug interactions

There are 613 drug interactions with Tykerb (lapatinib).

Tykerb disease interactions

There are 9 disease interactions with Tykerb (lapatinib) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer